Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNSP CNS Pharmaceuticals	$0.75 -6.9%	$0.98	$0.68 ▼ $62.00	$4.07M	2.58	704,405 shs	587,669 shs
CWBR CohBar	$0.41	$0.41	$0.00 ▼ $1.01	$1.19M	1.39	4,364 shs	N/A
DRMA Dermata Therapeutics	$0.69 +6.2%	$0.71	$0.57 ▼ $5.00	$4.43M	0.54	1.18 million shs	339,894 shs
GLTO Galecto	$3.61 +0.4%	$3.27	$2.01 ▼ $15.13	$4.76M	1.35	86,676 shs	90,500 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNSP CNS Pharmaceuticals	0.00%	-8.55%	+3.76%	-11.00%	-98.48%
CWBR CohBar	0.00%	0.00%	0.00%	0.00%	+70.48%
DRMA Dermata Therapeutics	0.00%	-4.65%	+0.18%	-4.27%	-60.76%
GLTO Galecto	0.00%	+1.82%	+8.26%	+48.35%	-74.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNSP CNS Pharmaceuticals	2.0956 of 5 stars	3.3	4.0	0.0	0.0	0.0	0.0	0.6
CWBR CohBar	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DRMA Dermata Therapeutics	1.8417 of 5 stars	3.5	4.0	0.0	0.0	0.6	0.8	0.0
GLTO Galecto	3.5038 of 5 stars	3.5	5.0	0.0	0.0	0.0	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNSP CNS Pharmaceuticals	2.50	Moderate Buy	$25.00	3,255.25% Upside
CWBR CohBar	0.00	N/A	N/A	N/A
DRMA Dermata Therapeutics	3.00	Buy	$3.00	331.72% Upside
GLTO Galecto	3.00	Buy	$10.00	177.32% Upside

Current Analyst Ratings Breakdown

Latest CWBR, CNSP, GLTO, and DRMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/22/2025	CNSP CNS Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/21/2025	DRMA Dermata Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $3.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	$5.37 per share	N/A
CWBR CohBar	N/A	N/A	N/A	N/A	$5.27 per share	N/A
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	$0.62 per share	N/A
GLTO Galecto	N/A	N/A	N/A	N/A	$10.99 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNSP CNS Pharmaceuticals	-$14.86M	-$3,748.50	N/A	∞	N/A	N/A	-385.41%	-193.20%	8/13/2025 (Estimated)
CWBR CohBar	-$12.18M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
DRMA Dermata Therapeutics	-$12.29M	-$16.41	N/A	∞	N/A	N/A	-270.81%	-179.96%	8/6/2025 (Estimated)
GLTO Galecto	-$21.44M	-$15.53	N/A	N/A	N/A	N/A	-98.27%	-84.29%	8/11/2025 (Estimated)

Latest CWBR, CNSP, GLTO, and DRMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	CNSP CNS Pharmaceuticals	N/A	-$1.58	N/A	-$1.58	N/A	N/A
5/14/2025	Q1 2025	DRMA Dermata Therapeutics	-$0.45	-$0.45	N/A	-$0.45	N/A	N/A
5/8/2025	Q1 2025	GLTO Galecto	N/A	-$1.92	N/A	-$1.92	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CWBR CohBar	N/A	N/A	N/A	N/A	N/A
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	N/A
GLTO Galecto	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNSP CNS Pharmaceuticals	N/A	4.94	4.94
CWBR CohBar	N/A	N/A	N/A
DRMA Dermata Therapeutics	N/A	3.70	3.70
GLTO Galecto	N/A	9.62	9.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNSP CNS Pharmaceuticals	14.02%
CWBR CohBar	2.47%
DRMA Dermata Therapeutics	8.67%
GLTO Galecto	14.20%

Insider Ownership

Company	Insider Ownership
CNSP CNS Pharmaceuticals	0.07%
CWBR CohBar	6.51%
DRMA Dermata Therapeutics	18.50%
GLTO Galecto	10.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNSP CNS Pharmaceuticals	5	5.46 million	5.46 million	Not Optionable
CWBR CohBar	10	2.91 million	N/A	Not Optionable
DRMA Dermata Therapeutics	8	6.38 million	5.20 million	Not Optionable
GLTO Galecto	40	1.32 million	1.18 million	Optionable

CWBR, CNSP, GLTO, and DRMA Headlines

Recent News About These Companies

Galecto, Inc. (GLTO) stock price, news, quote & history - Yahoo Finance

June 26, 2025 | sg.finance.yahoo.com

Galecto, Inc. Reports First Quarter 2025 Financial Results and Progress on AML Treatment Development

May 10, 2025 | nasdaq.com

Galecto, Inc.: Galecto Reports First Quarter 2025 Operating and Financial Results

May 9, 2025 | finanznachrichten.de

Galecto Reports First Quarter 2025 Operating and Financial Results

May 8, 2025 | globenewswire.com

Galecto (GLTO)

April 12, 2025 | es.investing.com

Galecto, Inc. Focuses on Oncology and Liver Diseases

April 3, 2025 | tipranks.com

Galecto trading halted, volatility trading pause

March 26, 2025 | markets.businessinsider.com

Galecto, Inc. Completes Strategic Review, Acquires Global Rights to GB3226 for Oncology and Liver Disease Focus

March 19, 2025 | quiverquant.comQ

Galecto Reports Full-Year 2024 Financial Results

March 19, 2025 | globenewswire.com

Galecto stock hits 52-week low at $4.39 amid market challenges

February 12, 2025 | msn.com

Galecto to Participate in Upcoming Investor Conferences

February 6, 2025 | globenewswire.com

When (GLTO) Moves Investors should Listen

January 1, 2025 | news.stocktradersdaily.comN

(GLTO) Technical Pivots with Risk Controls

November 29, 2024 | news.stocktradersdaily.comN

Galecto (NASDAQ:GLTO) Stock, Option Chain

November 15, 2024 | benzinga.com

Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

November 14, 2024 | zacks.com

Galecto, Inc. Announces Strategic Shift and Financial Overview

November 2, 2024 | markets.businessinsider.com

Galecto, Inc.’s Strategic Shift to Oncology and Liver Diseases: Navigating Risks and Opportunities

November 2, 2024 | tipranks.com

Galecto reports Q3 EPS ($3.39) vs ($7.50)

November 1, 2024 | msn.com

Galecto Reports Third Quarter 2024 Financial Results

November 1, 2024 | globenewswire.com

(GLTO) On The My Stocks Page

October 29, 2024 | news.stocktradersdaily.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

CWBR, CNSP, GLTO, and DRMA Company Descriptions

CNS Pharmaceuticals NASDAQ:CNSP

$0.75 -0.05 (-6.86%)

Closing price 04:00 PM Eastern

Extended Trading

$0.75 +0.00 (+0.39%)

As of 04:33 PM Eastern

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

CohBar NASDAQ:CWBR

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.

Dermata Therapeutics NASDAQ:DRMA

$0.69 +0.04 (+6.22%)

Closing price 03:59 PM Eastern

Extended Trading

$0.68 -0.01 (-1.42%)

As of 04:10 PM Eastern

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Galecto NASDAQ:GLTO

$3.63 +0.04 (+1.09%)

As of 04:00 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time